{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004128","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.417420+00:00","generated_at":"2026-06-20T18:03:25.244370+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AlloVir plans Phase 3 posoleucel enrollment completion in 2023; $234M cash","bullets":["Cash balance $234M as of Dec 31, 2022; FY 2023 operating expenses guided $150M-$170M.","Enrollment completion for all three posoleucel Phase 3 trials expected by end of 2023; data readouts in 2024.","Topline results from Phase 2 BKV treatment study in kidney transplant patients expected in Q1 2023.","Final Phase 2 multi-virus prevention data presented at ASH 2022 showed substantially lower infection rates.","CEO Diana Brainard to present at J.P. Morgan Healthcare Conference on Jan 10, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004128","json":"https://secwatch.observer/filing/0001193125-23-004128.json","markdown":"https://secwatch.observer/filing/0001193125-23-004128.md","text":"https://secwatch.observer/filing/0001193125-23-004128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523004128/0001193125-23-004128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523004128/d422387d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:03:25.244370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d8b3c9c4429bf187712179b9da1babd19b67d8a1","claim":"Kalaris Therapeutics, Inc. updated its fiscal year 2023 guidance (initiated).","evidence_excerpt":"For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash stock compensation expenses.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523004128/0001193125-23-004128-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}